BRIEF-Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application

Reuters
11 Feb
BRIEF-Biohaven Announces FDA Acceptance And Priority Review Of Troriluzole New Drug Application

Feb 11 (Reuters) - Biohaven BHVN.N:

  • BIOHAVEN ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF TRORILUZOLE NEW DRUG APPLICATION FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA

  • BIOHAVEN LTD - FDA DECISION ON TRORILUZOLE NDA EXPECTED BY 3Q2025

  • BIOHAVEN LTD - PREPARED TO COMMERCIALIZE TRORILUZOLE FOR SCA IN 2025

Source text: ID:nPnsctV5a

Further company coverage: BHVN.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10